| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/24/2011 | CA2382840C Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof |
| 05/24/2011 | CA2374215C New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| 05/24/2011 | CA2366090C Composition and method for inducing apoptosis in prostate cancer cells |
| 05/24/2011 | CA2366050C Agents for intravitreal administration to treat or prevent disorders of the eye |
| 05/24/2011 | CA2358459C Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions |
| 05/24/2011 | CA2345201C Mature protein having antagonistic activity against bone morphogenetic protein |
| 05/24/2011 | CA2344816C Medicinal aerosol formulation |
| 05/24/2011 | CA2342064C Long wave length absorbing bacteriochlorin alkyl ether analogs |
| 05/24/2011 | CA2341642C Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor |
| 05/24/2011 | CA2341507C Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them |
| 05/24/2011 | CA2319310C Equine fc epsilon receptor alpha chain nucleic acid molecules, corresponding proteins and uses thereof |
| 05/24/2011 | CA2303428C .alpha.-ketoamide multicatalytic protease inhibitors |
| 05/24/2011 | CA2266640C Methods for treating an ischemic disorder and improving stroke outcome |
| 05/24/2011 | CA2229631C Gene therapy using ovine adenoviral vectors |
| 05/24/2011 | CA2211687C Vascular endothelial growth factor-b |
| 05/19/2011 | WO2011060397A1 Substituted amino heterocycles useful as hiv antagonists |
| 05/19/2011 | WO2011060396A1 Aliphatic amines based heterocycles useful as hiv entry blockers |
| 05/19/2011 | WO2011060395A1 Cyclic ureas useful as hiv inhibitors |
| 05/19/2011 | WO2011060394A1 Compounds useful as chemokine receptor antagonists |
| 05/19/2011 | WO2011060392A1 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| 05/19/2011 | WO2011060391A1 Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| 05/19/2011 | WO2011060389A1 Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| 05/19/2011 | WO2011060330A1 Use of anti-bacterial agents for the treatment of epithelial-related conditions |
| 05/19/2011 | WO2011060321A1 Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof |
| 05/19/2011 | WO2011060320A1 Antisense antiviral compound and method for treating influenza viral infection |
| 05/19/2011 | WO2011060295A1 Kinase inhibitors |
| 05/19/2011 | WO2011060262A1 Crystalline forms of neurotrophin mimetic compounds and their salts |
| 05/19/2011 | WO2011060255A1 Reduced mass metformin formulations |
| 05/19/2011 | WO2011060235A1 Imidazole derivatives and methods of use thereof |
| 05/19/2011 | WO2011060217A1 Spiropiperidine compounds as orl-1 receptor antagonists |
| 05/19/2011 | WO2011060215A1 Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer |
| 05/19/2011 | WO2011060199A1 Boron-containing small molecules |
| 05/19/2011 | WO2011060196A1 Boron-containing small molecules |
| 05/19/2011 | WO2011060179A1 Use of peptide epoxyketones for metastasis suppression |
| 05/19/2011 | WO2011060129A1 Dynamic thermoresponsive nanoparticles for stabilization of enzymes at high temperatures |
| 05/19/2011 | WO2011060112A1 Deuterated tyrosine kinase inhibitors |
| 05/19/2011 | WO2011060083A1 Methods and compositions for rapid treatment of otitis externa |
| 05/19/2011 | WO2011060065A2 Instillation of liposomal formulation of sirna and antisense oligonucleotides |
| 05/19/2011 | WO2011060036A1 Bicyclic compounds and methods of use thereof |
| 05/19/2011 | WO2011060035A1 Spiropiperidine compounds as orl-1 receptor antagonists |
| 05/19/2011 | WO2011060026A1 Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah) |
| 05/19/2011 | WO2011060019A1 Androgen receptor modulator and uses thereof |
| 05/19/2011 | WO2011060000A1 Hepatitis c virus inhibitors |
| 05/19/2011 | WO2011059909A1 Polysaccharide gel formulation having multi-stage bioactive agent delivery |
| 05/19/2011 | WO2011059887A1 Hepatitis c virus inhibitors |
| 05/19/2011 | WO2011059881A1 Treatment of ophthalmic conditions with fluorenone derivatives |
| 05/19/2011 | WO2011059839A1 Bicyclic pyridines and analogs as sirtuin modulators |
| 05/19/2011 | WO2011059784A1 Tricyclic heterocyclic compounds |
| 05/19/2011 | WO2011059731A1 Alkynyl derivatives useful as dpp-1 inhibitors |
| 05/19/2011 | WO2011059610A1 Benzene sulfonamide thiazole and oxazole compounds |
| 05/19/2011 | WO2011059416A1 Prophylactic antioxidant agent for protecting the tissues of an organism from the action of negative ecological factors or the consequences of smoking tobacco |
| 05/19/2011 | WO2011059388A1 Oxazolo[4,5-c]pyridine substituted pyrazine |
| 05/19/2011 | WO2011059121A1 Salinomycin/inorganic-hydroxide nanohybrid material, pharmaceutical composition including same, and cancer treatment method using same |
| 05/19/2011 | WO2011059080A1 Isotope-substituted diamine derivative |
| 05/19/2011 | WO2011059075A1 Glutamic acid-rich and arginine-rich preparation |
| 05/19/2011 | WO2011059053A1 Therapeutic or prophylactic agent for diabetes |
| 05/19/2011 | WO2011059048A1 Novel amide derivative |
| 05/19/2011 | WO2011059042A1 Aromatic ring compound |
| 05/19/2011 | WO2011059037A1 Pharmaceutical composition for external use |
| 05/19/2011 | WO2011059021A1 8-azabicyclo[3.2.1]octane-8-carboxamide derivative |
| 05/19/2011 | WO2011058975A1 Agent for ameliorating postprandial hyperglycemia, and pyrrolidine iminosugar or salt thereof |
| 05/19/2011 | WO2011058964A1 Virus-inactivating agent |
| 05/19/2011 | WO2011058943A1 Pharmaceutical composition formed from combining compound having mch r1 antagonist activity and compound having npy y5 antagonist activity |
| 05/19/2011 | WO2011058933A1 Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing same |
| 05/19/2011 | WO2011058932A1 N-benzyl amide derivative and pharmaceutical composition containing same |
| 05/19/2011 | WO2011058923A1 Antibacterial agent for drug-resistant bacteria, method for screening for same, and use of same |
| 05/19/2011 | WO2011058905A1 Nitrobenzene derivative, highly-reactive-ros-generating agent using same, and method for generating highly-reactive ros |
| 05/19/2011 | WO2011058773A1 Oil-based composition |
| 05/19/2011 | WO2011058766A1 Aryl carboxamide derivatives as ttx-s blockers |
| 05/19/2011 | WO2011058763A1 Aminothiazine or aminooxazine derivative having amino linker |
| 05/19/2011 | WO2011058582A1 Histone deacetylase inhibitors for the treatment of fungal infections |
| 05/19/2011 | WO2011058579A1 Pharmaceutical combination of prostaglandin compound and nsaid for the treatment of glaucoma and ocular hypertension |
| 05/19/2011 | WO2011058522A1 Sorafenib ethylsulfonate salt, process for preparation and use |
| 05/19/2011 | WO2011058508A2 New compositions for the treatment of chemioresitant and/or potentially chemioresistant leukaemias |
| 05/19/2011 | WO2011058478A1 Substituted triazolopyrimidines as pde8 inhibitors |
| 05/19/2011 | WO2011058474A1 N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| 05/19/2011 | WO2011058473A1 N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| 05/19/2011 | WO2011058427A1 Palonosetron metabolites |
| 05/19/2011 | WO2011058374A1 Drug combination with theobromine and its use in therapy |
| 05/19/2011 | WO2011058366A1 Use of bethanechol for treatment of xerostomia |
| 05/19/2011 | WO2011058364A1 Method of treatment and screening method |
| 05/19/2011 | WO2011058346A1 Treatment of microbial infections |
| 05/19/2011 | WO2011058331A1 Pemirolast for the treatment of systemic low grade inflammation |
| 05/19/2011 | WO2011058280A1 Human fertility test using dpy19l2 |
| 05/19/2011 | WO2011058245A1 Novel mannopyranoside derivatives with anticancer activity |
| 05/19/2011 | WO2011058210A1 Formulations of cationic lipoamino acids with lower haemolytic power based on the formation of catanionic pairs |
| 05/19/2011 | WO2011058193A1 [1,5]-diazocin derivatives |
| 05/19/2011 | WO2011058183A1 Par-1 antagonists for use in the treatment or prevention of influenza virus type a infections |
| 05/19/2011 | WO2011058179A1 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide |
| 05/19/2011 | WO2011058154A1 Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators |
| 05/19/2011 | WO2011058149A1 Tricyclic pyrazol amine derivatives |
| 05/19/2011 | WO2011058139A1 A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
| 05/19/2011 | WO2011058122A1 Piperidine analogs as glycogen synthase activators |
| 05/19/2011 | WO2011058113A1 Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors |
| 05/19/2011 | WO2011058112A1 Fused bicyclic pyrazole derivatives as kinase inhibitors |
| 05/19/2011 | WO2011058111A1 Aminopurine derivatives as kinase inhibitors |
| 05/19/2011 | WO2011058110A1 Quinoline and quinoxaline derivatives as kinase inhibitors |
| 05/19/2011 | WO2011058109A1 Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors |
| 05/19/2011 | WO2011058108A1 Quinoline and quinoxaline derivatives as kinase inhibitors |
| 05/19/2011 | WO2011058027A2 N-9-substituted purine compounds, compositions and methods of use |